Skip to content
Viridian Theraputics
Engineering Medicines To Improve Patient Care
Menu
About Viridian
Leadership
Board of Directors
Pipeline
Approach
History of IGF-1R
Scientific Presentations
Patients
About TED
Clinical Trials
Careers
Investors
Press Releases
Events & Presentations
Scientific Presentations
Filings
Analyst Coverage
Corporate Governance
Governance Documents
Leadership
Board of Directors
Committee Composition
Investor Resources
Email Alerts
Contact
Published trial results show that an IGF-1R-blocking antibody reduces proptosis in TED patients